FIELD: measurement; testing.
SUBSTANCE: group of inventions relates to in vitro diagnosis and determination of the effectiveness of treating Gaucher's disease. In vitro method for diagnosing Gaucher's disease in a subject involves identifying a biomarker in a sample from a subject, determining the level of the biomarker present in the sample, and comparing the level of the biomarker with a threshold level. Free lyso-Gb1 acts as a biomarker, the threshold level for plasma and serum samples is 5 ng/ml, and for blood samples - 20 ng/ml. Also, the use of mass spectrometry in the diagnosis method, a method for determining the course of severity and methods for determining the effectiveness treating Gaucher's are disclosed.
EFFECT: group of inventions provides fast, simple and reliable diagnosis of Gaucher's disease.
12 cl, 12 dwg, 4 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR DIAGNOSTICS OF GAUCHER'S DISEASE | 2012 |
|
RU2780331C2 |
| COMPOSITIONS AND METHODS FOR TREATING GAUCHER DISEASE | 2010 |
|
RU2733466C2 |
| COMPOSITIONS AND METHODS FOR TREATING GAUCHER DISEASE | 2010 |
|
RU2568831C2 |
| TREATMENT OF PATHOLOGICAL BONE CONDITIONS IN PATIENTS WITH ACID SPHINGOMYELINASE DEFICIENCY | 2018 |
|
RU2795570C2 |
| METHOD FOR NUCLEOSOMES ADDUCTS DETECTION | 2012 |
|
RU2634266C2 |
| PROGNOSTIC METHOD FOR INDIVIDUALS WITH PROSTATE CANCER | 2013 |
|
RU2669809C2 |
| BIOMARKERS OF METHOTREXATE-INDUCED IMMUNE TOLERANCE | 2018 |
|
RU2795201C2 |
| METHOD FOR DETERMINING PRESENCE OR ABSENCE OF AGGRESSIVE PROSTATE CANCER | 2013 |
|
RU2675370C2 |
| ARIMOCLOMOL FOR TREATMENT OF GLUCOCEREBROSIDASE-ASSOCIATED DISORDERS | 2017 |
|
RU2750154C2 |
| POLYUNSATURATED FATTY ACIDS FOR TREATING DEMENTIA, AND PRE-DEMENTIA RELATED CONDITIONS | 2006 |
|
RU2444356C2 |
